Treatment
Azacitidine clinical trials
We’re tracking 178 recruiting studies that include Azacitidine, each written for real people, not researchers, below.
Recruiting studies
- NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Phoenix, ArizonaAges 18 years+ - NCT05381038RecruitingPhase 1/Phase 2
Personalized azacitidine combinations for breast or stomach cancer
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
SingaporeAges 21–99 - NCT07646821RecruitingPhase 1/Phase 2
New drug combo for MDS or AML with TP53 gene changes
This trial tests a new combination of two drugs, ropeginterferon alfa-2b and azacitidine, for people with MDS or AML who have a change in the TP53 gene. The goal is to see if this combination can help control the disease and possibly improve outcomes.
Houston, TexasAges 18 years+ - NCT07651163Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy regimens for newly diagnosed blood cancer
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hangzhou, ZhejiangAges 15–65 - NCT06647862RecruitingPhase 3
Testing a new drug combo for newly diagnosed CMML
This trial tests whether adding the experimental drug IMM01 to standard azacitidine works better than azacitidine alone for people with chronic myelomonocytic leukemia (CMML). The goal is to see if the combination can help control the disease with manageable side effects.
Hefei, AnhuiAges 18 years+ - NCT06502145RecruitingPhase 1
Iadademstat with hypomethylating agent for MDS
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
Milwaukee, WisconsinAges 18 years+ - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT03161223RecruitingPhase 1/Phase 2
Durvalumab plus other medicines for peripheral T-cell lymphoma
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
Charlottesville, VirginiaAges 18 years+ - NCT05736965RecruitingPhase 2
Selinexor with azacitidine and venetoclax for new AML
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
ChangzhouAges 18 years+ - NCT05817955RecruitingPhase 2
Azacitidine plus ruxolitinib for higher-risk MDS/MPN
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Nanjing, JiangsuAges 18–80 - NCT05675813RecruitingPhase 1/Phase 2
Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06190067RecruitingPhase 2
Azacitidine plus PD-1 for relapsed Hodgkin lymphoma
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06256627Recruiting
Maintenance treatment of 'ITIVA' for AML in remission
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
Zhengzhou, HenanAges 14 years+ - NCT07388563RecruitingPhase 1
Combination drug therapy for returning T-cell lymphoma
This trial tests two drugs, azacitidine and abatacept, given together for T-cell lymphoma that has come back or not improved after earlier treatment. The goal is to see if this combination can control the cancer better, potentially offering a new option for patients.
Bethesda, MarylandAges 18–120 - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT04905810RecruitingPhase 2
Azacitidine or decitabine plus venetoclax for AML after prior failure
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Clovis, CaliforniaAges 18 years+ - NCT07813390Enrolling by invitationPhase 2
New drug combo for leukemia that is no longer responding to venetoclax
This trial tests a combination of three drugs—homoharringtonine, lisaftoclax, and azacitidine—for people with acute myeloid leukemia (AML) whose cancer did not respond to or has returned after prior treatment with venetoclax. The goal is to see if this new combination can help control the leukemia when current options have failed.
Guangzhou, GuangdongAges 18 years+ - NCT07743112RecruitingPhase 2
Study of a new drug combo for untreated acute myeloid leukemia
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
TianjinAges 18 years+ - NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06073769Recruiting
Safety study of oral azacitidine for AML in Korea
This study is monitoring the safety of the drug oral azacitidine (also called Onureg) when given as maintenance therapy to adults with acute myeloid leukemia (AML). It is designed to track how well patients tolerate the medicine in real-world use in Korea.
SeoulAges 19 years+ - NCT07645469RecruitingPhase 1
WT1-targeting T cells with azacitidine for AML
This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.
Seattle, WashingtonAges 18 years+ - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT07548983RecruitingPhase 1
Maintenance therapy after stem cell transplant for AML
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Portland, OregonAges 18 years+
What Azacitidine is being studied for
Conditions with recruiting Azacitidine studies.
Common questions
- Are there clinical trials studying Azacitidine?
- Yes. Clin2 currently lists 178 recruiting studies that include Azacitidine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Azacitidine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Azacitidine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Azacitidine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.